Neurocrine Biosciences Ownership | Who Owns Neurocrine Biosciences?


OverviewForecastRevenueFinancialsChartTranscripts

Neurocrine Biosciences Ownership Summary


Neurocrine Biosciences is owned by 27.28% institutional investors, 1.05% insiders, and 71.67% retail investors. Blackrock is the largest institutional shareholder, holding 14.22% of NBIX shares. Dodge & Cox Stock I is the top mutual fund, with 4.01% of its assets in Neurocrine Biosciences shares.

NBIX Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockNeurocrine Biosciences27.28%1.05%71.67%
SectorHealthcare Stocks 42.54%10.83%46.63%
IndustrySpecialty & Generic Drug Manufacturers Stocks26.16%11.89%61.94%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock14.19M14.22%$1.95B
Blackrock funding, inc. /de12.71M12.83%$1.78B
Vanguard group9.71M9.80%$1.36B
Dodge & cox5.56M5.61%$780.04M
Jpmorgan chase4.73M4.78%$664.02M
State street4.35M4.39%$610.16M
Price t rowe associates inc /md/2.87M2.90%$402.43M
Renaissance2.42M2.44%$339.48M
Geode capital management2.02M2.05%$283.50M
Aqr capital management1.90M1.88%$258.93M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Sarissa capital management lp303.15K23.59%$42.56M
Boone capital management166.41K7.66%$23.36M
Eagle health investments lp162.80K6.00%$22.85M
Healthinvest partners ab102.63K5.67%$1.53M
Bellevue group1.76M5.14%$247.50M
First turn management181.90K3.83%$25.53M
Braidwell lp880.28K3.67%$123.57M
Birchview capital, lp28.69K3.04%$4.03M
Avidity partners management lp220.40K2.95%$30.08M
Iron triangle partners lp131.39K2.62%$18.44M

Top Buyers

HolderShares% AssetsChange
Jpmorgan chase4.73M0.04%468.40K
Los angeles capital management1.20M0.57%458.11K
Blackrock14.19M0.04%429.74K
Two sigma investments, lp347.56K0.07%347.56K
Norges bank325.30K0.01%325.30K

Top Sellers

HolderShares% AssetsChange
Dsm capital partners---932.60K
Point72 asset management---837.43K
Ubs asset management americas765.24K0.02%-622.40K
Jupiter asset management---582.79K
Westfield capital management co lp---484.78K

New Positions

HolderShares% AssetsChangeValue
Norges bank325.30K0.01%325.30K$44.40M
Axa investment managers323.90K0.12%323.90K$45.47M
First turn management181.90K3.83%181.90K$25.53M
Soleus capital management138.00K0.98%138.00K$19.37M
Rakuten investment management128.74K0.03%128.74K$8.62M

Sold Out

HolderChange
Wealthtrak capital management-1.00
Crewe advisors-2.00
Rosenberg matthew hamilton-4.00
Dt investment partners-5.00
Ameritas advisory services-5.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 2025313-46.40%27,003,435-70.64%270.32%165-45.54%95-55.40%
Jun 30, 20255880.17%97,956,5484.05%981.11%30220.32%215-15.02%
Mar 31, 2025585-3.94%94,105,380-0.29%941.07%246-24.31%25722.38%
Dec 31, 2024555-5.77%87,755,246-5.34%861.03%288-3.36%196-2.97%
Sep 30, 2024585-3.31%92,570,293-1.20%911.06%297-9.17%2006.38%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Dodge & Cox Stock I3.96M4.01%-
iShares Core S&P Mid-Cap ETF3.22M3.25%-
Vanguard US Total Market Shares ETF3.20M3.21%2.53K
Vanguard Total Stock Mkt Idx Inv3.12M3.14%-71.50K
Vanguard Small Cap Index2.40M2.42%-15.57K
BB Biotech AG Ord1.82M1.80%-40.00K
Vanguard Small Cap Growth Index Inv1.35M1.36%-3.15K
Vanguard Windsor Investor Shares1.13M1.14%-2.80K
JPM US Mid Cap Growth-Composite1.12M1.13%543.28K
JPMorgan Mid Cap Growth I1.11M1.12%-3.53K

Recent Insider Transactions


DateNameRoleActivityValue
Dec 08, 2025Lippoldt Darin Chief Legal OfficerSell$698.62K
Dec 03, 2025LYONS GARY A-Sell$2.29M
Nov 28, 2025BENEVICH ERIC Chief Commercial OfficerSell$905.88K
Nov 25, 2025MORROW GEORGE J-Sell$2.15M
Nov 05, 2025RASTETTER WILLIAM H-Sell$2.73M

Insider Transactions Trends


DateBuySell
2025 Q4-6
2025 Q3-4
2025 Q2-2
2025 Q1-45
2024 Q4-4

NBIX Ownership FAQ


Who Owns Neurocrine Biosciences?

Neurocrine Biosciences shareholders are primarily institutional investors at 27.28%, followed by 1.05% insiders and 71.67% retail investors. The average institutional ownership in Neurocrine Biosciences's industry, Specialty & Generic Drug Manufacturers Stocks, is 26.16%, which Neurocrine Biosciences exceeds.

Who owns the most shares of Neurocrine Biosciences?

Neurocrine Biosciences’s largest shareholders are Blackrock (14.19M shares, 14.22%), Blackrock funding, inc. /de (12.71M shares, 12.83%), and Vanguard group (9.71M shares, 9.80%). Together, they hold 36.86% of Neurocrine Biosciences’s total shares outstanding.

Does Blackrock own Neurocrine Biosciences?

Yes, BlackRock owns 14.22% of Neurocrine Biosciences, totaling 14.19M shares as of Jun 2024. This represents 0.04% of BlackRock's total assets, with a market value of 1.95B$. In the last quarter, BlackRock increased its holdings by 429.74K shares, a 3.12% change.

Who is Neurocrine Biosciences’s biggest shareholder by percentage of total assets invested?

Sarissa capital management lp is Neurocrine Biosciences’s biggest shareholder by percentage of total assets invested, with 23.59% of its assets in 303.15K Neurocrine Biosciences shares, valued at 42.56M$.

Who is the top mutual fund holder of Neurocrine Biosciences shares?

Dodge & Cox Stock I is the top mutual fund holder of Neurocrine Biosciences shares, with 4.01% of its total shares outstanding invested in 3.96M Neurocrine Biosciences shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools